Shuttle Pharmaceuticals Holdings (Shuttle Pharmaceuticals Holdings) Sloan Ratio % : -44.01% (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Shuttle Pharmaceuticals Holdings Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Shuttle Pharmaceuticals Holdings's Sloan Ratio for the quarter that ended in Mar. 2024 was -44.01%.

Warning Sign:

When sloan ratio (30.54)% higher than 25% or lower than -25%, earnings are more likely to be made up of accruals.

As of Mar. 2024, Shuttle Pharmaceuticals Holdings has a Sloan Ratio of -44.01%, indicating earnings are more likely to be made up of accruals.

Shuttle Pharmaceuticals Holdings Sloan Ratio % Historical Data

The historical data trend for Shuttle Pharmaceuticals Holdings's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shuttle Pharmaceuticals Holdings Sloan Ratio % Chart

Shuttle Pharmaceuticals Holdings Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Sloan Ratio %

-141.18

30.54

Shuttle Pharmaceuticals Holdings Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Sloan Ratio %	Get a 7-Day Free Trial									-	-	-	30.54	-44.01

Competitive Comparison of Shuttle Pharmaceuticals Holdings's Sloan Ratio %

For the Drug Manufacturers - Specialty & Generic subindustry, Shuttle Pharmaceuticals Holdings's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shuttle Pharmaceuticals Holdings's Sloan Ratio % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shuttle Pharmaceuticals Holdings's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Shuttle Pharmaceuticals Holdings's Sloan Ratio % falls into.

Shuttle Pharmaceuticals Holdings Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Shuttle Pharmaceuticals Holdings's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio	=	(Net Income (A: Dec. 2023 )	-	Cash Flow from Operations (A: Dec. 2023 )
	-	Cash Flow from Investing (A: Dec. 2023 ))	/	Total Assets (A: Dec. 2023 )
	=	(-6.593	-	-5.581
	-	-2.83)	/	5.952
	=	30.54%

Shuttle Pharmaceuticals Holdings's Sloan Ratio for the quarter that ended in Mar. 2024 is calculated as

Sloan Ratio	=	(Net Income (TTM)	-	Cash Flow from Operations (TTM))
	-	Cash Flow from Investing (TTM))	/	Total Assets (Q: Mar. 2024 )
	=	(-7.349	-	-5.482
	-	0.225)	/	4.754
	=	-44.01%

Shuttle Pharmaceuticals Holdings's Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was -2.184 (Jun. 2023 ) + -1.793 (Sep. 2023 ) + -1.641 (Dec. 2023 ) + -1.731 (Mar. 2024 ) = $-7.35 Mil.
Shuttle Pharmaceuticals Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 was -1.646 (Jun. 2023 ) + -1.535 (Sep. 2023 ) + -1.062 (Dec. 2023 ) + -1.239 (Mar. 2024 ) = $-5.48 Mil.
Shuttle Pharmaceuticals Holdings's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 was 0.063 (Jun. 2023 ) + -0.026 (Sep. 2023 ) + 0.087 (Dec. 2023 ) + 0.101 (Mar. 2024 ) = $0.23 Mil.

Shuttle Pharmaceuticals Holdings (NAS:SHPH) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Mar. 2024, Shuttle Pharmaceuticals Holdings has a Sloan Ratio of -44.01%, indicating earnings are more likely to be made up of accruals.

Shuttle Pharmaceuticals Holdings Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Shuttle Pharmaceuticals Holdings's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.

Shuttle Pharmaceuticals Holdings (Shuttle Pharmaceuticals Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shuttle Pharmaceuticals Holdings Inc (NAS:SHPH) » Definitions » Sloan Ratio %

Comparable Companies

Traded in Other Exchanges

N/A

Address

One Research Court, Suite 450, Rockville, MD, USA, 20850

Website

https://www.shuttlepharma.com

Shuttle Pharmaceuticals Holdings Inc is a clinical stage pharmaceutical company leveraging our proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments by leveraging insights into the pillars of cancer therapy: surgery, radiation therapy, chemotherapy, and immunotherapy.

Executives

Milton Brown	director	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Bette Jacobs	director	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., 1 RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Peter Dritschilo	officer: President and COO	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., SUITE 450, ROCKVILLE MD 20850
Anatoly Dritschilo	director, 10 percent owner, officer: CEO and Chairman	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Tyvin Rich	officer: Chief Medical Officer	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Mira Jung	officer: Chief Scientific Officer	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Hoek Michael Vander	officer: Chief Financial Officer	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., SUITE 450, ROCKVILLE MD 20850
Steven M Richards	director	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
William Adkins	director	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Joshua Schafer	director	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Chris Senanayake	director	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850